Targeted Genetics to Present at Rodman & Renshaw Techvest Global Healthcare Conference
11 5월 2004 - 11:00PM
PR Newswire (US)
Targeted Genetics to Present at Rodman & Renshaw Techvest
Global Healthcare Conference SEATTLE, May 11 /PRNewswire-FirstCall/
-- H. Stewart Parker, President and Chief Executive Officer of
Targeted Genetics Corporation , will speak at the Rodman &
Renshaw Techvest Global Healthcare Conference on Thursday, May 13,
2004. Ms. Parker will provide a corporate overview, along with
highlights from the Company's cystic fibrosis, AIDS vaccine and
arthritis programs. Presentation details are as follows: What:
Rodman & Renshaw Techvest Global Healthcare Conference Where:
London, England Claridge's Hotel When: Thursday, May 13, 2004 8:00
AM BST A live and archived version of Ms. Parker's presentation
will be available at http://www.targetedgenetics.com/. Targeted
Genetics Corporation develops gene-based products for preventing
and treating acquired and inherited diseases. The Company has three
clinical product development programs, targeting cystic fibrosis,
AIDS prophylaxis and rheumatoid arthritis. The Company also has a
promising pipeline of product candidates focused on hemophilia and
cancer and a broad platform of gene delivery technologies, as well
as a promising body of technology for cellular therapy under
development by its subsidiary company, CellExSys. For more
information about the Company, visit its website at
http://www.targetedgenetics.com/. NOTE: This release contains
forward-looking statements regarding our product pipeline and
clinical trials. These statements involve current expectations,
forecasts of future events and other statements that are not
historical facts. Inaccurate assumptions and known and unknown
risks and uncertainties can affect the accuracy of forward-looking
statements. Actual results could differ materially from
expectations for a number of reasons, including our failure to make
progress with our clinical trials, our failure to obtain positive
results from our preclinical or clinical programs, our failure to
obtain or maintain regulatory approvals, our failure to maintain or
protect our intellectual and the other risks described in the
section entitled "Factors Affecting Our Operating Results, Our
Business and Our Stock Price" in our quarterly report on Form 10-Q
for the quarter ended March 31, 2004. You should not rely unduly on
these forward-looking statements, which apply only as of the date
of this release. We undertake no duty to publicly announce or
report revisions to these statements as new information becomes
available that may change our expectations. DATASOURCE: Targeted
Genetics Corporation CONTACT: Courtney Self of Targeted Genetics
Corporation, +1-206-521-7392 Web site:
http://www.targetedgenetics.com/
Copyright
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024